Literature DB >> 27082308

MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer.

Haitao Guan1, Zhijun Dai1, Yuguang Ma1, Zhongwei Wang1, Xiaoxu Liu1, Xijing Wang.   

Abstract

MicroRNAs (miRNAs or miRs) regulate gene expression by negatively modulating the stability or translational efficiency of their target genes by targeting the 3'-untranslated region (3'-UTR). Aberrant miRNA expression has been reported in various types of cancer; miRNAs can function as either oncogenes or tumor suppressor genes in cancer. In this study, we examined the expression level of miR‑101 in breast cancer tissues and cell lines by RT-qPCR, and found that miR‑101 expression was downregulated in breast cancer tissues and cell lines; indeed, in 6 of the 28 tissue samples, miR‑101 could not be detected. Furthermore, miR‑101, when transfected into SKBR3 cells, inhibited cell proliferation and promoted apoptosis, while miR‑101 inhibitor had the opposite effect. A dual-luciferase reporter assay revealed that miR‑101 targeted the 3'-UTR of eyes absent homolog 1 (Drosophila) (EYA1). Western blot analysis demonstrated a significantly decreased protein level of EYA1 in the SKBR3 cells transfected with miR‑101 mimic, whereas transfection with miR‑101 inhibitor led to an increased level of EYA1. Moreover, an increased expression of EYA1 was also found in breast cancer tissues and cell lines. The silencing of EYA1 using siRNA targeting EYA1 (EYA1‑siRNA) significantly inhibited SKBR3 cell proliferation and promoted apoptosis, and also suppressed the increased proliferation induced by transfection with miR‑101 inhibitor. The protein expression levels of Notch signaling components (jagged1, Hes1 and Hey1) were significantly decreased by transfection with miR‑101 mimic and EYA1-siRNA, and were increased by transfection with miR‑101 inhibitor. Furthermore, the elevated protein expression levels of jagged1, Hes1 and Hey1 induced by transfection with miR‑101 inhibitor in the SKBR3 cells were significantly decreased by transfection with EYA1-siRNA. Taken together, these results suggest that miR‑101 is down-regulated in breast cancer, and can inhibit cell proliferation and promote apoptosis by targeting EYA1 through the Notch signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27082308     DOI: 10.3892/ijmm.2016.2557

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  19 in total

1.  Is the regulation by miRNAs of NTPDase1 and ecto-5'-nucleotidase genes involved with the different profiles of breast cancer subtypes?

Authors:  Fernanda Cardoso da Silva; Angelo Borges de Melo Neto; Christina Aparecida Martins; Thaís Cunha de Sousa Cardoso; Matheus de Souza Gomes; Thaise Gonçalves de Araújo; Cristina Ribas Fürstenau
Journal:  Purinergic Signal       Date:  2021-11-05       Impact factor: 3.765

Review 2.  The role of epigenetic modifications in drug resistance and treatment of breast cancer.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Arash Kiani; Fateme Jalalifar; Parisa Osati; Mahsa Akbari Oryani; Fateh Shakeri; Farhad Nasirzadeh; Behman Khalesi; Mohsen Nabi-Afjadi; Hamidreza Zalpoor; Maysam Mard-Soltani; Zahra Payandeh
Journal:  Cell Mol Biol Lett       Date:  2022-06-28       Impact factor: 8.702

3.  Downregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression.

Authors:  Yuu Saitoh; Tomohiro Umezu; Satoshi Imanishi; Michiyo Asano; Seiichiro Yoshizawa; Seiichiro Katagiri; Tamiko Suguro; Hiroaki Fujimoto; Daigo Akahane; Chiaki Kobayashi-Kawana; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Oncol Lett       Date:  2020-01-09       Impact factor: 2.967

Review 4.  Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential.

Authors:  Dharambir Kashyap; Hardeep Singh Tuli; Vivek Kumar Garg; Neelam Goel; Anupam Bishayee
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

5.  1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p.

Authors:  Yingyu Ma; Wei Luo; Brittany L Bunch; Rachel N Pratt; Donald L Trump; Candace S Johnson
Journal:  Oncotarget       Date:  2017-07-27

6.  Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.

Authors:  Chun-Yao Li; Dan-Dan Xiong; Chun-Qin Huang; Rong-Quan He; Hai-Wei Liang; Deng-Hua Pan; Han-Lin Wang; Yi-Wen Wang; Hua-Wei Zhu; Gang Chen
Journal:  Med Sci Monit       Date:  2017-04-18

7.  Identification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line.

Authors:  Jia Gu; TongJuan Li; Lei Zhao; Xue Liang; Xing Fu; Jue Wang; Zhen Shang; Wei Huang; Jianfeng Zhou
Journal:  Biomed Res Int       Date:  2017-02-21       Impact factor: 3.411

8.  Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs.

Authors:  Srinivas V Koduru; Ashley N Leberfinger; Yuka I Kawasawa; Milind Mahajan; Niraj J Gusani; Arun J Sanyal; Dino J Ravnic
Journal:  Sci Rep       Date:  2018-05-22       Impact factor: 4.379

9.  Measuring plasma levels of three microRNAs can improve the accuracy for identification of malignant breast lesions in women with BI-RADS 4 mammography.

Authors:  Julia Alejandra Pezuk; Thiago Luiz Araujo Miller; José Luiz Barbosa Bevilacqua; Alfredo Carlos Simões Dornellas de Barros; Felipe Eduardo Martins de Andrade; Luiza Freire de Andrade E Macedo; Vera Aguilar; Amanda Natasha Menardo Claro; Anamaria Aranha Camargo; Pedro Alexandre Favoretto Galante; Luiz F L Reis
Journal:  Oncotarget       Date:  2017-09-11

10.  MicroRNA‑4530 suppresses cell proliferation and induces apoptosis by targeting RASA1 in human umbilical vein endothelial cells.

Authors:  Li Jing; Hong Li; Tao Zhang; Jianxin Lu; Lianjin Zhong
Journal:  Mol Med Rep       Date:  2019-03-01       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.